You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 20, 2024

CLINICAL TRIALS PROFILE FOR MIRENA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for mirena

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00185380 ↗ Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS) Completed Bayer Phase 2 2005-04-01 The purpose of this study is to investigate if drug doses lower than the one released from Mirena® would be as effective for contraception as Mirena®. Subjects participating in the study will be randomly assigned to be inserted with any of the three different intrauterine systems (IUSs). The IUSs are nearly alike except that the amount of hormone released from them is different.
NCT00360490 ↗ Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS) Completed Bayer Phase 3 2006-07-01 The purpose of this study is to determine whether the levonorgestrel-releasing intrauterine system is effective in decreasing menstrual blood loss.
NCT00393198 ↗ Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Completed Bayer Phase 4 2006-10-01 The purpose of this study is to assess the bleeding pattern during the last 3 months of the first MIRENA® and the first year of the second MIRENA® use.
NCT00445887 ↗ Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Completed National Cancer Institute (NCI) Phase 2 2008-03-10 This randomized phase II trial is studying how well levonorgestrel works in preventing ovarian cancer in patients at high risk for ovarian cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of levonorgestrel may prevent ovarian cancer.
NCT00445887 ↗ Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Completed Gynecologic Oncology Group Phase 2 2008-03-10 This randomized phase II trial is studying how well levonorgestrel works in preventing ovarian cancer in patients at high risk for ovarian cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of levonorgestrel may prevent ovarian cancer.
NCT00475228 ↗ 'Levonorgestrel IUD Insertion After D&E Procedure Completed University of Pittsburgh Phase 4 2007-03-01 This study is a randomized controlled trial of insertion of the levonorgestrel-releasing intrauterine device (LNG-IUD) immediately following dilation & evacuation (D&E) compared to delayed insertion 3-6 weeks post-D&E. Eighty-eight women undergoing D&E between 15 0/7 and 23 6/7 weeks gestation will be enrolled at Magee-Womens Hospital, Pittsburgh, PA. The primary outcome is LNG-IUD usage six months following enrollment. We hypothesize that more women receiving immediate insertion will be using the LNG-IUD 6 months after the D&E procedure than women receiving delayed insertion. Secondary outcomes include the proportion receiving an IUD, continuation rate, complication rates, subject satisfaction, and quality of life. The utility of ultrasonography in predicting expulsion will also be examined. Anticipated problems include poor subject follow-up and coordinating the intra-operative study procedures.
NCT00498784 ↗ HR-QoL and Sexuality in Mirena Inserted Contraception Users Completed Bayer Phase 4 2005-11-01 The purpose of this study is to evaluate the changes in the quality of life, as well as in the sexual activity, in women inserted with MIRENA, a hormonal contraceptive intra-uterine system, over the first 12 months of use. Patients switching from oral contraception to an intrauterine contraceptive device (here: MIRENA) will be observed in the first year post MIRENA insertion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for mirena

Condition Name

Condition Name for mirena
Intervention Trials
Contraception 25
Menorrhagia 7
Atypical Endometrial Hyperplasia 5
Endometrial Hyperplasia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for mirena
Intervention Trials
Menorrhagia 13
Hyperplasia 13
Endometrial Hyperplasia 12
Endometrial Neoplasms 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for mirena

Trials by Country

Trials by Country for mirena
Location Trials
United States 120
Brazil 6
Canada 5
Ireland 5
United Kingdom 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for mirena
Location Trials
Colorado 7
Pennsylvania 7
Georgia 6
Virginia 6
Texas 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for mirena

Clinical Trial Phase

Clinical Trial Phase for mirena
Clinical Trial Phase Trials
Phase 4 20
Phase 3 6
Phase 2/Phase 3 4
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for mirena
Clinical Trial Phase Trials
Completed 45
Recruiting 8
Unknown status 5
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for mirena

Sponsor Name

Sponsor Name for mirena
Sponsor Trials
Bayer 22
Society of Family Planning 5
Fudan University 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for mirena
Sponsor Trials
Other 72
Industry 25
NIH 7
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.